Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds

More than 40% of compounds identified through combinatorial screening programs are poorly soluble in water. These molecules are difficult to formulate using conventional approaches and are associated with innumerable formulation-related performance issues. Formulating these compounds as pure drug nanoparticles is one of the newer drug-delivery strategies applied to this class of molecules. Nanoparticle dispersions are stable and have a mean diameter of less than 1 micron. The formulations consist of water, drug, and one or more generally regarded as safe excipients. These liquid dispersions exhibit an acceptable shelf-life and can be postprocessed into various types of solid dosage forms. Drug nanoparticles have been shown to improve bioavailability and enhance drug exposure for oral and parenteral dosage forms. Suitable formulations for the most commonly used routes of administration can be identified with milligram quantities of drug substance, providing the discovery scientist with an alternate avenue for screening and identifying superior analogs. For the toxicologist, the approach provides a means for dose escalation using a formulation that is commercially viable. In the past few years, formulating poorly water-soluble compounds using a nanoparticulate approach has evolved from a conception to a realization whose versatility and applicability are just beginning to be realized.

[1]  S. Baumgartner,et al.  Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. , 2006, International journal of pharmaceutics.

[2]  S. Waldman,et al.  The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[3]  A. Noyes,et al.  The rate of solution of solid substances in their own solutions , 1897 .

[4]  J. Astier,et al.  Crystallization mechanisms in solution , 1988 .

[5]  Rainer H Müller,et al.  Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  G. Poste,et al.  Lipid vesicles as carriers for introducing biologically active materials into cells. , 1976, Methods in cell biology.

[7]  C. Lipinski Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .

[8]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[9]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[10]  J. Dressman,et al.  Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.

[11]  L W White,et al.  Plenty of room at the bottom. , 2001, Journal of clinical orthodontics : JCO.

[12]  J. Donnelly,et al.  Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation , 2006, Antimicrobial Agents and Chemotherapy.

[13]  G Vergnault,et al.  Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound , 2005, Drug development and industrial pharmacy.

[14]  E. Merisko-Liversidge,et al.  Insulin Nanoparticles: A Novel Formulation Approach for Poorly Water Soluble Zn-Insulin , 2004, Pharmaceutical Research.

[15]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[16]  J. Fréchet,et al.  Designing dendrimers for drug delivery. , 1999, Pharmaceutical science & technology today.

[17]  Gloria Kwei,et al.  The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. , 2004, International journal of pharmaceutics.

[18]  G. W. Pace,et al.  Novel injectable formulations of insoluble drugs , 1999 .

[19]  I. Wilding,et al.  Site-specific drug delivery in the gastrointestinal tract. , 2000, Critical reviews in therapeutic drug carrier systems.

[20]  A. Florence,et al.  The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat , 1996 .

[21]  Koji Takahashi,et al.  Microemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription design. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Beate Bittner,et al.  Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. , 2002, Current opinion in drug discovery & development.

[23]  M. Odomi,et al.  Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[24]  G S Gazelle,et al.  Percutaneous computed tomography lymphography in the rabbit by subcutaneously injected nanoparticulates. , 1994, Academic radiology.

[25]  S. Griffey,et al.  Indirect computed tomography lymphography using iodinated nanoparticles to detect cancerous lymph nodes in a cutaneous melanoma model. , 1996, Academic radiology.

[26]  George Poste,et al.  Site–Specific (Targeted) Drug Delivery in Cancer Therapy , 1983, Bio/Technology.

[27]  J. Rieger,et al.  Organic Nanoparticles in the Aqueous Phase-Theory, Experiment, and Use. , 2001, Angewandte Chemie.

[28]  M. Prato,et al.  Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Juliano Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions , 1988 .

[30]  J. Guillet,et al.  Drug Delivery Systems , 1995 .

[31]  Rainer H. Müller,et al.  Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .

[32]  D. Papahadjopoulos Liposome formation and properties: an evolutionary profile. , 1988, Biochemical Society transactions.

[33]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[34]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[35]  D. McCarthy,et al.  Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat , 1992 .

[36]  S. Baumgartner,et al.  Pharmaceutical Nanotechnology Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs , 2006 .

[37]  B. Lorber,et al.  The crystallization of biological macromolecules from precipitates : evidence for Ostwald ripening , 1996 .

[38]  S. Davis,et al.  Nanoparticles in drug delivery. , 1987, Critical reviews in therapeutic drug carrier systems.

[39]  R. Müller,et al.  Influence of high pressure homogenisation equipment on nanodispersions characteristics. , 2000, International journal of pharmaceutics.

[40]  W. Ostwald Studien über die Bildung und Umwandlung fester Körper , 1897 .

[41]  Clive G. Wilson,et al.  Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape , 1982 .

[42]  C. Pouton,et al.  Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[43]  K. Letchford,et al.  A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[44]  G. Liversidge,et al.  Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .

[45]  S. Davis,et al.  Lipid Emulsions as Drug Delivery Systems , 1987, Annals of the New York Academy of Sciences.

[46]  Elaine Merisko-Liversidge,et al.  Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.